MR Microstructural Imaging for Prostate Cancer Diagnosis

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
AgeNot listed
SponsorFirst Affiliated Hospital of Zhejiang University

About this trial

The goal of this multi-center clinical study is to evaluate whether time-dependent diffusion MRI (TDDMRI) can provide reliable microstructural imaging markers for the diagnosis of prostate cancer. The main questions this study aims to answer are:

* Do TDDMRI-derived microstructural parameters (such as cell size and density) improve diagnostic accuracy for prostate cancer compared with conventional MRI? * How well do the microstructural parameters correlate with whole-slide pathology findings? * Can the investigators determine diagnostic models combining multiple features for presurgical diagnosis across multiple centers?

Participants with suspected prostate cancer will undergo 3T MRI including TDDMRI. Microstructural parameters will be quantified and compared with standard multiparametric MRI. All participants will also receive prostate biopsy or prostatectomy, and imaging findings will be validated against histopathology.

This study will:

* Collect TDDMRI and conventional MRI data from six hospitals. * Derive and validate imaging markers of prostate cancer based on microstructural parameters. * Compare diagnostic performance across centers and against pathology as the reference standard.

Eligibility criteria

Qualifiers

Clinical suspicion of prostate cancer (elevated PSA, abnormal digital rectal examination, or other clinical indication).

Undergoing prostate MRI including TDDMRI as part of diagnostic evaluation. Able and willing to provide written informed consent.

Disqualifiers

Contraindications to MRI (e.g., pacemaker, ferromagnetic implants, severe claustrophobia).

Prior treatment for prostate cancer (surgery, radiation, hormonal therapy, chemotherapy).

Severe comorbid conditions precluding MRI or biopsy.

Inability to provide informed consent.

Trial design

Treatments tested in this trial

  • MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)

Treatment groups

2,000 Participants
are divided into 1 treatment group

Sponsors and collaborators

First Affiliated Hospital of Zhejiang University

Lead sponsor

Zhejiang University

Collaborator

Jiangsu Provincial People's Hospital

Collaborator

The First Affiliated Hospital of Dalian Medical University

Collaborator

Zhejiang Hospital

Collaborator

Henan Cancer Hospital

Collaborator

Beijing Hospital

Collaborator